Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
- PMID: 37221018
- PMCID: PMC10547452
- DOI: 10.1093/infdis/jiad172
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
Abstract
Background: Despite scale-up of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) in children 3-59 months of age in Burkina Faso, malaria incidence remains high, raising concerns regarding SMC effectiveness and selection of drug resistance. Using a case-control design, we determined associations between SMC drug levels, drug resistance markers, and presentation with malaria.
Methods: We enrolled 310 children presenting at health facilities in Bobo-Dioulasso. Cases were SMC-eligible children 6-59 months of age diagnosed with malaria. Two controls were enrolled per case: SMC-eligible children without malaria; and older (5-10 years old), SMC-ineligible children with malaria. We measured SP-AQ drug levels among SMC-eligible children and SP-AQ resistance markers among parasitemic children. Conditional logistic regression was used to compute odds ratios (ORs) comparing drug levels between cases and controls.
Results: Compared to SMC-eligible controls, children with malaria were less likely to have any detectable SP or AQ (OR, 0.33 [95% confidence interval, .16-.67]; P = .002) and have lower drug levels (P < .05). Prevalences of mutations mediating high-level SP resistance were rare (0%-1%) and similar between cases and SMC-ineligible controls (P > .05).
Conclusions: Incident malaria among SMC-eligible children was likely due to suboptimal levels of SP-AQ, resulting from missed cycles rather than increased antimalarial resistance to SP-AQ.
Keywords: amodiaquine; antimalarial resistance; malaria; seasonal malaria chemoprevention; sulfadoxine-pyrimethamine.
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Figures




Similar articles
-
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.Lancet. 2020 Dec 5;396(10265):1829-1840. doi: 10.1016/S0140-6736(20)32227-3. Lancet. 2020. PMID: 33278936 Free PMC article.
-
Predictors of caregiver adherence to administration of amodiaquine during delivery of seasonal malaria chemoprevention in Nigeria, Burkina Faso, Chad, and Togo.Malar J. 2023 May 5;22(1):148. doi: 10.1186/s12936-023-04576-5. Malar J. 2023. PMID: 37147685 Free PMC article.
-
Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali.PLoS Med. 2020 Aug 21;17(8):e1003214. doi: 10.1371/journal.pmed.1003214. eCollection 2020 Aug. PLoS Med. 2020. PMID: 32822362 Free PMC article. Clinical Trial.
-
Systematic Review and Meta-Analysis of Seasonal Malaria Chemoprevention.Am J Trop Med Hyg. 2023 Dec 11;110(1):20-31. doi: 10.4269/ajtmh.23-0481. Print 2024 Jan 3. Am J Trop Med Hyg. 2023. PMID: 38081050 Free PMC article.
-
Pharmacokinetic considerations in seasonal malaria chemoprevention.Trends Parasitol. 2022 Aug;38(8):673-682. doi: 10.1016/j.pt.2022.05.003. Epub 2022 Jun 7. Trends Parasitol. 2022. PMID: 35688778 Review.
Cited by
-
Malaria prevention in children: an update.Curr Opin Pediatr. 2024 Apr 1;36(2):164-170. doi: 10.1097/MOP.0000000000001332. Epub 2024 Jan 22. Curr Opin Pediatr. 2024. PMID: 38299986 Free PMC article. Review.
-
Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso.Sci Rep. 2024 Oct 16;14(1):24224. doi: 10.1038/s41598-024-75369-2. Sci Rep. 2024. PMID: 39414909 Free PMC article.
-
Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso.Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0153423. doi: 10.1128/aac.01534-23. Epub 2024 Feb 27. Antimicrob Agents Chemother. 2024. PMID: 38411062 Free PMC article.
-
Seasonal malaria chemoprevention and mutations in Pfdhfr and Pfdhps genes in children in the health district of Nanoro, Burkina Faso.Malariaworld J. 2025 Mar 17;16:5. doi: 10.5281/zenodo.15039792. eCollection 2025. Malariaworld J. 2025. PMID: 40124705 Free PMC article.
-
Prevalence of asymptomatic parasitaemia among household members of children under seasonal malaria chemoprevention coverage and comparison of the performance of standard rapid diagnostic tests versus ultrasensitive RDT for the detection of asymptomatic parasitaemia in Nanoro, Burkina Faso.Parasitol Res. 2024 Nov 15;123(11):383. doi: 10.1007/s00436-024-08380-1. Parasitol Res. 2024. PMID: 39542934 Free PMC article.
References
-
- World Health Organization (WHO) . WHO guidelines for malaria. Geneva, Switzerland: WHO, 2022.
-
- World Health Organization (WHO) . World malaria report 2022. Geneva, Switzerland: WHO, 2022.